Department of Pediatrics, University College of Medical Sciences and Guru Teg Bahadur Hospital, Dilshad Garden, Delhi, India.
Indian Pediatr. 2012 Jun;49(6):449-54. doi: 10.1007/s13312-012-0073-x. Epub 2011 Aug 15.
To determine the role of oral vitamin D supplementation for resolution of severe pneumonia in under-five children.
Randomized, double blind, placebo-controlled trial.
Inpatients from a tertiary care hospital.
Two hundred children [mean (SD) age: 13.9 (11.7) months; boys: 120] between 2 months to 5 years with severe pneumonia. Pneumonia was diagnosed in the presence of fever, cough, tachypnea (as per WHO cut-offs) and crepitations. Children with pneumonia and chest indrawing or at least one of the danger sign (inability to feed, lethargy, cyanosis) were diagnosed as having severe pneumonia. The two groups were comparable for baseline characteristics including age, anthropometry, socio-demographic profile, and clinical and laboratory parameters.
Oral vitamin D (1000 IU for <1 year and 2000 IU for >1 year) (n=100) or placebo (lactose) (n=100) once a day for 5 days, from enrolment. Both the groups received antibiotics as per the Indian Academy of Pediatrics guidelines, and supportive care (oxygen, intravenous fluids and monitoring).
Primary: time to resolution of severe pneumonia. Secondary: duration of hospitalization and time to resolution of tachypnea, chest retractions and inability to feed.
Median duration (SE, 95% CI) of resolution of severe pneumonia was similar in the two groups [vitamin D: 72 (3.7, 64.7-79.3) hours; placebo: 64 (4.5, 55.2-72.8) hours]. Duration of hospitalization and time to resolution of tachypnea, chest retractions, and inability to feed were also comparable between the two groups.
Short-term supplementation with oral vitamin D (1000-2000 IU per day for 5 days) has no beneficial effect on resolution of severe pneumonia in under-five children. Further studies need to be conducted with higher dose of Vitamin D or longer duration of supplementation to corroborate these findings.
确定口服维生素 D 补充剂在治疗 5 岁以下儿童重症肺炎中的作用。
随机、双盲、安慰剂对照试验。
一家三级保健医院的住院患者。
200 名 2 至 5 岁的儿童(平均[标准差]年龄:13.9[11.7]个月;男孩:120 人)患有重症肺炎。肺炎的诊断标准为发热、咳嗽、呼吸急促(按世界卫生组织的标准)和喘鸣。患有肺炎和胸部内陷或至少有一个危险征象(不能进食、嗜睡、发绀)的儿童被诊断为患有重症肺炎。两组在基线特征方面具有可比性,包括年龄、人体测量、社会人口学特征以及临床和实验室参数。
口服维生素 D(1 岁以下为 1000IU,1 岁以上为 2000IU)(n=100)或安慰剂(乳糖)(n=100),每天一次,共 5 天,从入组开始。两组均根据印度儿科学会指南使用抗生素,并给予支持性治疗(吸氧、静脉补液和监测)。
主要结局为重症肺炎缓解时间。次要结局为住院时间以及呼吸急促、胸部凹陷和不能进食缓解时间。
两组重症肺炎缓解的中位时间(SE,95%CI)相似[维生素 D:72(3.7,64.7-79.3)小时;安慰剂:64(4.5,55.2-72.8)小时]。两组住院时间以及呼吸急促、胸部凹陷和不能进食缓解时间也相似。
短期口服维生素 D(每天 1000-2000IU,连续 5 天)补充对 5 岁以下儿童重症肺炎的缓解无有益作用。需要进行更多剂量的维生素 D 或更长时间的补充治疗研究来证实这些发现。